55.87

0.70% -0.1984

Crinetics Pharmaceuticals Inc (CRNX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CRNX Giù? Forum Previsione

Precedente Chiudi:

$56.07

Aprire:

$56

Volume 24 ore:

15,830

Relative Volume:

0.02

Capitalizzazione di mercato:

$5.20B

Reddito:

$4.72M

Utile/perdita netta:

$-258.54M

Rapporto P/E:

-16.38

EPS:

-3.41

Flusso di cassa netto:

$-185.05M

1 W Prestazione:

-6.67%

1M Prestazione:

-5.14%

6M Prestazione:

+12.48%

1 anno Prestazione:

+85.97%

Intervallo 1D:

$55.30

$56.65

Intervallo di 1 settimana:

$52.84

$60.15

Portata 52W:

$29.72

$62.53

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

Nome

Crinetics Pharmaceuticals Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

858-450-6464

Indirizzo

10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA

Dipendente

210

Cinguettio

@Crinetics

Prossima data di guadagno

2024-11-12

Ultimi documenti SEC

CRNX's Discussions on Twitter

Confronta CRNX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CRNX	55.90	5.20B	4.72M	-258.54M	-185.05M	-3.41
VRTX	446.42	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	738.52	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	586.49	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.16	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.51	24.49B	3.30B	-501.07M	1.03B	11.54

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-03-06	Iniziato	Citigroup	Buy
2024-01-16	Iniziato	Morgan Stanley	Overweight
2023-12-21	Iniziato	Jefferies	Hold
2023-11-20	Ripresa	JP Morgan	Overweight
2023-10-24	Ripresa	Cantor Fitzgerald	Overweight
2023-08-31	Iniziato	Oppenheimer	Outperform
2023-04-24	Iniziato	Piper Sandler	Overweight
2023-03-30	Iniziato	Robert W. Baird	Outperform
2021-11-30	Iniziato	JMP Securities	Mkt Outperform
2021-11-23	Iniziato	Evercore ISI	Outperform
2021-06-18	Aggiornamento	JP Morgan	Neutral → Overweight
2019-12-23	Iniziato	ROTH Capital	Buy
2019-02-14	Iniziato	H.C. Wainwright	Buy
2018-08-13	Iniziato	JP Morgan	Neutral
2018-08-13	Iniziato	Leerink Partners	Outperform
2018-08-13	Iniziato	Piper Jaffray	Overweight

Mostra tutto

Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie

Nov 20, 2024

Jennison Associates LLC Acquires 13,470 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat

Nov 20, 2024

Victory Capital Management Inc. Purchases 116,657 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat

Nov 20, 2024

Nov 19, 2024

First Turn Management LLC Cuts Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat

Nov 19, 2024

Nov 18, 2024

Steven Cohen's Recent Transaction in Crinetics Pharmaceuticals Inc - GuruFocus.com

Nov 15, 2024

Crinetics Pharmaceuticals : 2024 Citi Global Healthcare Conference - Marketscreener.com

Nov 15, 2024

Crinetics Pharmaceuticals : Piper Sandler 36th Annual Healthcare Conference - Marketscreener.com

Nov 15, 2024

Crinetics Pharmaceuticals : 2024 Evercore 7th Annual HealthCONx Conference - Marketscreener.com

Nov 15, 2024

Crinetics Pharmaceuticals : 2024 Cantor Global Healthcare Conference - Marketscreener.com

Nov 15, 2024

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences - The Manila Times

Nov 15, 2024

Crinetics Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | CRNX Stock News - StockTitan

Nov 15, 2024

EcoR1 Capital, LLC Increases Stake in Crinetics Pharmaceuticals Inc - GuruFocus.com

Nov 15, 2024

HC Wainwright Has Pessimistic View of CRNX FY2024 Earnings - MarketBeat

Nov 15, 2024

Crinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 52-Week High Following Analyst Upgrade - Defense World

Nov 15, 2024

Nov 14, 2024

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline - GlobeNewswire

Nov 14, 2024

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting - The Manila Times

Nov 14, 2024

Crinetics Unveils Breakthrough Cancer Drug Platform, Reports Positive Phase 2 Trial Results | CRNX Stock News - StockTitan

Nov 14, 2024

Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) - Yahoo Finance

Nov 14, 2024

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 14, 2024

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

Nov 14, 2024

Nov 13, 2024

Crinetics Pharmaceuticals (NASDAQ:CRNX) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat

Nov 13, 2024

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024